1. Standard of Care & Key Clinical Challenges
Epithelial ovarian cancer—and specifically High-Grade Serous Ovarian Carcinoma (HGSOC)—remains the fifth leading cause of cancer-related mortality in women, with an overall 5-year survival rate of approximately 47% that drops to 29% in advanced HGSOC.
Conventional Modalities: Standard frontline treatment relies on cytoreductive surgery paired with platinum-based chemotherapy (cisplatin or carboplatin), taxanes (paclitaxel), anti-angiogenic antibodies (bevacizumab), and poly-ADP-ribose polymerase (PARP) inhibitors (olaparib, veliparib, rucaparib, niraparib).
High Recurrence & Genetic Constraints: Approximately 70% of patients relapse within three years following standard surgery and chemotherapy. While PARP inhibitors target homologous recombination deficiencies, germline or somatic BRCA1/2 mutations occur in only ~20% of HGSOC cases, leaving most patients ineligible or non-responsive. Furthermore, over 96% of HGSOC tumors express p53 mutations, driving widespread chemoresistance.
2. Repurposed Anthelmintics & Benzimidazoles in Ovarian Cancer
To bypass chemoresistance and target cancer stem cell (CSC) populations, several repurposed antiparasitic compounds demonstrate potent anti-tumor activity in preclinical ovarian cancer models:
Ivermectin (IVM):
KPNB1 & PAK1 Blockade: Inhibits ovarian cancer proliferation by inactivating PAK1 kinase and blocking KPNB1 (a nuclear transport factor), inducing cell cycle arrest and apoptosis.
Chemotherapeutic Synergy: In vivo combination with paclitaxel results in near-complete tumor growth inhibition. Additionally, ivermectin enhances cisplatin efficacy in epithelial ovarian cancer by suppressing the Akt/mTOR pathway.
Albendazole (ABZ):
Overcoming Paclitaxel Resistance: Inhibits tubulin polymerization and cell proliferation in paclitaxel-resistant ovarian cancer cell lines (such as 1A9PTX22).
Anti-Angiogenic Effects: Suppresses vascular endothelial growth factor (VEGF) production, significantly impairing tumor angiogenesis and malignant ascites formation in nude mouse models of peritoneal ovarian cancer (e.g., OVCAR-3).
Mebendazole (MBZ):
Reversing Cisplatin Resistance: Suppresses ovarian cancer growth and maintenance while overcoming cisplatin resistance through the multi-pathway inhibition of survival signaling cascades.
Synergy with p53 Reactivators: Exhibits synergistic cytotoxic activity when combined with mutant p53-targeting agents such as APR-246.
Fenbendazole & Niclosamide:
Fenbendazole (FZ): Nanoparticle-encapsulated fenbendazole (PLGA formulation) or polymeric micelle combinations with rapamycin significantly reduce cell viability and induce apoptosis in epithelial ovarian cancer cells.
Niclosamide: Disrupts cellular bioenergetics and downregulates canonical Wnt/β-catenin, mTOR, and STAT3 signaling pathways to eradicate ovarian cancer tumor-initiating stem cells.
3. Emerging Targeted, p53-Based, and Combination Modalities
Given the high prevalence of p53 mutations in ovarian cancer, next-generation targeted strategies are under active investigation:
Mutant p53 Reactivators: APR-246 (PRIMA-1MET) restores wild-type p53 function and has shown high disease control rates in phase II clinical trials when combined with pegylated liposomal doxorubicin or carboplatin in platinum-resistant HGSOC.
Small-Molecule Stabilizers: Agents such as Kevetrin (activates/stabilizes p53), PC14586 (targets Y220C p53 mutations), and SHetA2 (targets mortalin/p53 complexes) are designed to induce cell cycle arrest and apoptosis across heterogeneous tumor populations.
Arsenic Trioxide (ATO): Synergizes with cisplatin in paclitaxel-resistant ovarian cancer cells and triggers dual apoptosis and ferroptosis when combined with PARP inhibitors like olaparib.
Sources:
Categorized by primary drug focus and clinical research scope:
1. Mebendazole-Focused Clinical & Preclinical Studies
Blum, C. B., McMenamin, M., Khoo, T., Edwin, J. M., Jose, P., & O’Callaghan, L. A. (2026). From anthelmintic to neuro-oncology: A systematic review of mebendazole repurposing for brain tumour therapy. British Journal of Clinical Pharmacology, 1–28. https://doi.org/10.1002/bcp.70565
Meco, D., Attinà, G., Mastrangelo, S., Navarra, P., & Ruggiero, A. (2023). Emerging perspectives on the antiparasitic mebendazole as a repurposed drug for the treatment of brain cancers. International Journal of Molecular Sciences, 24(2), Article 1334. https://doi.org/10.3390/ijms24021334
Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y. S., Fang, H. B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., et al. (2017). The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget, 8(8), 12576–12595. https://doi.org/10.18632/oncotarget.12968
Trinova Health. (2026). Mebendazole and Cancer Metabolism: What a New 2026 Glioma Study Suggests. Trinova Health Oncology Insights. https://trinovahealth.com/mebendazole-cancer-metabolism-glioma-2026/
Video Source 2. (2025). This Isn’t Experimental: A Simple Way to Reduce Cancer Metastasis #cancerremission [YouTube Video].
2. Fenbendazole-Focused Preclinical & Case Studies
Chiang, R. H., et al. (2021). Fenbendazole Enhancing Antitumor Effect: A Case Series of Complete Remission in Advanced Genitourinary Cancers. [Clinical Case Series Report].
Duan, W. Q., et al. (2013). Evaluation of Fenbendazole In Vitro and In Vivo in Preclinical Mammary Tumor Models. NIH Public Access Manuscript (NIHMS443674).
TroubleFree Cancer Research. (2026). Fenbendazole for Lung Cancer: Research Review 2026.
https://fenbendazole-lung-cancer-review-2026.org
Video Source 1. (2024). FenBen in Stage 4 Cancer [YouTube Video].
Yamaguchi, T., Shimizu, J., Oya, Y., Horio, Y., & Hida, T. (2021). Drug-induced liver injury in a patient with non-small cell lung cancer after the self-administration of fenbendazole based on social media information. Case Reports in Oncology, 14(2), 886–891. https://doi.org/10.1159/000516276
3. Albendazole-Focused Preclinical Studies
Tao, R., et al. (2019). Antitumor effects and mechanisms of repurposed benzimidazole carbamates in solid tumors. OncoTargets and Therapy / Oncology Letters, 21(5), Article 12656. https://doi.org/10.2147/OTT.S188502
Zhang, L., et al. (2019). Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC). BioMed Research International, 2019, Article 3689517. https://doi.org/10.1155/2019/3689517
4. Ivermectin-Focused Research & Reviews
Juarez, M., Schcolnik-Cabrera, A., & Dueñas-Gonzalez, A. (2020). The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug. International Journal of Oncology, 56(3), 651–663. https://doi.org/10.3892/ijo.2020.4962
Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Yang, F. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, Article 105207. https://doi.org/10.1016/j.phrs.2020.105207
5. Dual-Agent & Combination Protocol Studies
Baghli, I., Makis, W., Marik, P. E., Gonzalez, M. J., Grant, W. B., Hunninghake, R., Levy, T. E., Lim, H., Cheng, R. Z., Bondarenko, I., Bousquet, P., Ortiz, R., Mary, M., D’Agostino, D. P., & Martinez, P. (2024). Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. Journal of Orthomolecular Medicine, 39(3), 1–28.
CancerChoices. (2024). Mebendazole or Fenbendazole: Are you a health professional? CancerChoices Integrative Oncology Guide. https://cancerchoices.org/therapy/mebendazole-or-fenbendazole/for-health-professionals/
Hulscher, N., Victory, K., Thorp, J. A., Pinsky, D., Diaz-Villalobos, A., Gillooly, P., Coulson, F., Annazone, M., Radesi, C., Brooks, J., McCullough, P. A., & Risch, H. (2026). Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: Results from a prospective observational cohort. Anticancer Research, 46(7), 3243–3255. https://doi.org/10.21873/anticanres.18194
Integrative Medicine: A Clinician’s Journal. (2026). Repurposed antiparasitic protocols in integrative oncology practice. Integrative Medicine: A Clinician’s Journal (IMCJ), 25(3), 27–34.
6. Comprehensive Benzimidazole & Anthelmintic Class Reviews
Aroua, L. M., Alminderej, F. M., Almuhaylan, H. R., et al. (2025). Benzimidazole(s): Synthons, bioactive lead structures, total synthesis, and the profiling of major bioactive categories. RSC Advances / OncoTargets and Therapy, 12, 471–478.
Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Alvarez Moreno, J. C., Polit, F., Lopez, O., Merhe, A., Abou-Kheir, W., Nieder, A. M., Poppiti, R., & Omarzai, Y. (2022). Overcoming drug resistance in advanced prostate cancer by drug repurposing. Medical Sciences, 10(1), Article 15. https://doi.org/10.3390/medsci10010015
Benzimidazole Derivatives as Repurposed Anticancer Agents. (2022). Benzimidazole-derivatives.pdf [Academic Review Monograph].
Benzimidazole Derivatives & Ivermectin in Oncology: Cellular Mechanisms and Multimodal Scaffolds. (2024). Benzimidazole-derivatives222.pdf [Academic Research Text].
Heo, D. S. (2020). Anthelmintics as potential anti-cancer drugs? Journal of Korean Medical Science / Korean Journal of Physiology & Pharmacology, 35(10), Article e75 / 26(5), 377–384. https://doi.org/10.3346/jkms.2020.35.e75
Laudisi, F., Marônek, M., Di Grazia, A., Monteleone, G., & Stolfi, C. (2022). Repositioning of anthelmintic drugs for the treatment of cancer. International Journal of Molecular Sciences, 23(8), Article 4315. https://doi.org/10.3390/ijms23084315
Markowitz, L. B., et al. (2017). Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism. OncoTargets and Therapy, 10, 5633–5642. https://doi.org/10.2147/OTT.S144703
Mrkvová, Z., Uldrijan, S., Pombinho, A., Bartůněk, P., & Slaninová, I. (2025). Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in tumor cells. Molecules, 30(5), Article 2377. https://doi.org/10.3390/molecules30052377
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2023). Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. Cancers, 15(11), Article 2972. https://doi.org/10.3390/cancers15112972
Oncology Research Group. (2023). Benzimidazole anthelmintics in cancer chemotherapy and tumor microenvironment modulation. Biotechnology and Bioprocess Engineering / Biomedicine & Pharmacotherapy, 31(1), 1–15.
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2023). Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics. Biomolecules, 13(1), Article 159. https://doi.org/10.3390/biom13010159
Thorat, M. A., et al. (2025). Drug repositioning in oncology: Progress, challenges, and clinical prospects. Cancer Cell International, 25, Article 138. https://doi.org/10.1186/s12935-025-03138-w